HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) — Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development will be participating in the following upcoming investor conferences.
2022 Wells Fargo Healthcare Conference
Date: Thursday, September 8, 2022
Format: 1×1 Meetings only
Location: Boston, MA
Morgan Stanley 20th Annual Global Healthcare Conference
Date: Monday, September 12, 2022
Format: 1×1 Meetings only
Location: New York, NY
Cantor Oncology, Hematology & HemeOnc Conference
Date: Wednesday, September 28, 2022
Format: Panel Presentation and 1×1 Meetings
Panel: Cell Therapy in Solid Tumors
Location: New York, NY
About Alaunos Therapeutics
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has a clinical and strategic collaboration with the National Cancer Institute. For more information, please visit www.alaunos.com.
Investor Relations Contact:
Alex Lobo
Stern Investor Relations
[email protected]
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
